Title:
COMPOUND WITH ANTI-KRAS MUTANT TUMOR ACTIVITY
Document Type and Number:
WIPO Patent Application WO/2024/041606
Kind Code:
A1
Abstract:
The present invention provides a compound represented by formula (I) for use as a KRAS inhibitor, a pharmaceutical composition comprising the compound, a method for preparing the compound, and use of the compound in treating a cancer.
Inventors:
SHANG ERCHANG (CN)
ZHONG BOYU (US)
ZHANG TONY YANTAO (US)
SONG GUANGLIN (CN)
ZHENG AIJUN (CN)
CHEN GUOMENG (CN)
HOU FULIANG (CN)
WANG RUIXIANG (CN)
DONG CHUNLAN (CN)
ZHONG BOYU (US)
ZHANG TONY YANTAO (US)
SONG GUANGLIN (CN)
ZHENG AIJUN (CN)
CHEN GUOMENG (CN)
HOU FULIANG (CN)
WANG RUIXIANG (CN)
DONG CHUNLAN (CN)
Application Number:
PCT/CN2023/114683
Publication Date:
February 29, 2024
Filing Date:
August 24, 2023
Export Citation:
Assignee:
TYLIGAND BIOSCIENCE SHANGHAI LTD (CN)
International Classes:
C07D487/04; A61K31/407; A61K31/435; A61K31/4375; A61K31/517; A61K31/519; A61P35/00; C07D401/14; C07D403/04; C07D471/02; C07D471/04; C07D487/02; C07D519/00
Domestic Patent References:
| WO2023159087A1 | 2023-08-24 | |||
| WO2023018812A1 | 2023-02-16 | |||
| WO2022132200A1 | 2022-06-23 | |||
| WO2022173870A1 | 2022-08-18 | |||
| WO2022248885A2 | 2022-12-01 | |||
| WO2023020519A1 | 2023-02-23 | |||
| WO2022256459A1 | 2022-12-08 | |||
| WO2023173017A1 | 2023-09-14 | |||
| WO2023020523A1 | 2023-02-23 | |||
| WO2020113071A1 | 2020-06-04 | |||
| WO2020146613A1 | 2020-07-16 |
Other References:
DATABASE REGISTRY 6 March 2023 (2023-03-06), ANONYMOUS : "1,4-Oxazepine-2-acetonitrile, 4-[7-(8-ethynyl-7-fluoro-3-hydroxy-1- naphthalenyl)-8-fluoro-2-[[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin- 7a(5H)-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]hexahydro- (CA INDEX NAME)", XP093142305, retrieved from STN Database accession no. 2904565-28-0
Attorney, Agent or Firm:
ZHONGZI LAW OFFICE (CN)
Download PDF: